CASP3 and neoplasm: Levels of the apoptotic marker cleaved caspase 3, in tumour tissue taken from the docetaxel followed by selumetinib group, increased in this combination group (16.8-fold change from the control; P<0.0005) compared with the single agents alone (3.5- and 2.4-fold change for docetaxel and selumetinib, respectively) (Figure 4Aiii PD2).